Disclaimer
This program was supported by a non-CME sponsorship grant from Jazz Pharmaceuticals.
Exploration of Real-World Evidence on the Efficacy and Safety of CPX-351 in Patients with Deep Secondary AML
Faculty
This educational program has been developed with the assistance of:
Disclosures
Faculty Disclosures:
Dr LeBlanc is currently, or has recently, been a consultant for or received honoraria from AbbVie, Agilix, Agios/Servier, Apellis, Astellas, BMS/Celgene, Genentech, Geron, Gilead, GSK, Lilly, Menarini/Stemline, Novartis, Novo Nordisk, Pfizer, Syndax, and Taiho; has served on recent advisory boards for AbbVie, Agios/Servier, and BMS; has received honoraria from AbbVie, Agios/Servier, Astellas, BMS/Celgene, GSK, Incyte, Menarini-Stemline, and Rigel for recent speaking engagements; has equity interest in Dosentrx and Thyme Care; has received recent research funding from AbbVie, the American Cancer Society, AstraZeneca, BMS, Deverra Therapeutics, Duke University, GSK, Jazz Pharmaceuticals, the Leukemia and Lymphoma Society and the National Institute of Nursing Research/ National Institutes of Health; and has received royalties from UpToDate.
The information presented is intended for educational purposes only and does not constitute medical advice. It is not meant to represent the only or best methods or procedures appropriate for the medical situations discussed. Rather, it reflects the views, statements, or opinions of the authors or presenters, which may be of interest or value to other healthcare professionals. Responsibility for patient care resides with the healthcare professional, based on their clinical judgment, experience, and knowledge of the individual patient.
For full prescribing information—including indications, contraindications, warnings, precautions, and adverse events—please refer to the approved product labeling. Note that labeling may vary by geographical location. In the United States, prescribing information is available from the U.S. Food and Drug Administration (www.fda.gov), and in Europe, from the European Medicines Agency (www.ema.europa.eu).
This activity is intended for healthcare professionals practicing in the United States. To proceed, please confirm that you are a healthcare professional practicing in the U.S.
